RECENT NEWS
July 13, 2014:
Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17 Read More...
RECENT NEWS
April, 2017: ALSP announced that it has had the great good fortune to have Steve Jacobsen, Ph.D. accept the position of CEO and take a seat on its Board. Steve has been advising the Company for a number of years and became available when he left his position as Senior Project Director of Neuroscience iMed at AstraZeneca. Steve brings with him many years' experience in drug development for neurodegeneration and a world class reputation in the space, and we are proud to welcome him onboard. Dr. Pierschbacher will remain with the Company and is very much looking forward to working with Steve in his new leadership capacity.
June, 2016: Vivian Hook, Ph.D., UCSD, and Gregory Hook, Ph.D., ALSP Inc., will present scientific papers at the National Neurotrauma Society Meeting, June 26-29, 2016, in Lexington, Kentucky, and at the Gordon Research Conference on Neurobiology of Brain Disorders, August 7-12, 2016, in Girona, Spain.
April 6, 2016: ALSP, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims directed to a group of ALP-496-related compounds, which ALSP had earlier licensed from Columbia University. Michael Pierschbacher, Ph.D, CEO, stated, "This issuance significantly increases the depth of our patent-approved pipeline of potential drug candidates." Read More...
March 1 - 2, 2016: ALSP Inc. presented its recent research findings at the 'GTC 2nd Protease Inhibitors in Drug Discovery' meeting in San Diego. As a Keynote speaker, Vivian Hook, Ph.D., UCSD, presented "Cathepsin B is a Validated Drug Target for Traumatic Brain Injury" and Gregory Hook, Ph.D., ALSP Inc., presented the poster "E64d, a Cysteine Protease Inhibitor, Provides a Viable Translational Opportunity for Development of Therapeutics for TBI". Read More...
February 10, 2016: ALSP Inc. announced that it has appointed Col.(Retired) Dallas C. Hack, MD as Consultant for Medical Affairs in preparation for its move into clinical trials with its lead drug. Michael Pierschbacher, PhD, CEO, stated, "We are pleased to welcome Dallas Hack onto the ALSP team. We look forward to working with an individual of such practical knowledge and far-reaching experience in Traumatic Brain Injury (TBI). We look forward to drawing deeply on his broad experience and success as a clinician and researcher in this area as we enter into our next stage of growth, clinical development." Read More...
January 25 - 27, 2016: ALSP Inc. presented its recent research findings at the Keystone Symposia on Molecular and Cellular Biology in Santa Fe, New Mexico. Vivian Hook, Ph.D., UCSD, presented "Cathepsin B is a Validated Drug Target for Traumatic Brain Injury" during a session entitled "From Precision Medicine to Therapies (TBI)". Gregory Hook, PhD, ALSP, presented the poster "E64d, a Cysteine Protease Inhibitor, Provides a Viable Translational Opportunity for Development of Therapeutics for TBI", reviewing small molecule cysteine protease inhibitors shown to be effective in a number of TBI-related animal models and describing the selection of a lead clinical candidate. Read More...
September 15, 2015: ALSP Inc. is pleased to announce that it has entered into a Cooperative Research and Development Agreement (CRADA) with Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, to conduct traumatic brain injury (TBI) research on the Company's primary therapeutic target, cathepsin B, and the use of the Company's compounds to effect TBI outcomes in animal models. Read More...
September 2, 2015: ALSP Inc. announced the publication of the article "Cathepsin B is a new Drug target for traumatic Brain Injury Therapeutics: Evidence for E64d as a promising lead Drug candidate" by Gregory Hook, J.Steven Jacobsen, Kenneth Grabstein, Mark Kindy and Vivian Hook. Read more about the promising treatment here, and the publication is available here...
June 29, 2015: The poster entitled "Brain cathepsin B is elevated following trauma in both mild-closed and severe-penetrating traumatic brain injury models", was presented at the National Society of Neurotrauma, Santa Fe, NM, by researchers at the Walter Reed Army Institute of Research, Silver Spring, MD, and co-authored by Drs. Greg Hook, VP ALSP Research, and Vivian Hook, Professor, UCSD, and ALSP Advisor Read More...
February 2, 2015: ALSP Inc. announced today that it has signed a license agreement with Columbia University to develop a series of proprietary compounds that are related to its lead clinical drug candidate, ALP-496, in the field of neurodegenerative disease Read More...
resented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17 Read More...
Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17 Read More...
RECENT NEWS
July 13, 2014:
Drs. Greg Hook, VP Alzheimer’s Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer’s International Conference (AAIC) in Copenhagen, Denmark July 12– 17 Read More...
RECENT NEWS
July 13, 2014:RECENT NEWS
